CD40-CD40L: Linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications

Diabetes and Vascular Disease Research

Volumn 10, Issue 2, 2013, Pages 115-122

  Seijkens, Tom ^a   Kusters, Pascal ^b   Engel, David ^b   Lutgens, Esther ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CD40; CD40L; inflammation; Type 2 diabetes mellitus; vascular complications

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; METFORMIN; PITAVASTATIN; ROSIGLITAZONE; TROGLITAZONE;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; DRUG EFFECT; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; VASCULITIS;

ADIPOSE TISSUE; ANTIGENS, CD40; CD40 LIGAND; DIABETES MELLITUS, TYPE 2; HUMANS; PANCREATITIS; VASCULITIS;

EID: 84874051661     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112455817     Document Type: Review

References (69)

1. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008 ; 371: 1800-1809
2. Conget I, Gimenez M. Glucose control and cardiovascular disease: is it important? No. Diabetes Care. 2009 ; 32: S334 - S336
3. Van Dieren S, Beulens JW, Van Der Schouw YT, et al. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010 ; 17: S3 - S8
4. King H, Aubert RE, and Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998 ; 21: 1414-1431
5. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011 ; 11: 98-107
6. Engel D, Seijkens T, Poggi M, et al. The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. Semin Immunol. 2009 ; 21: 308-312
7. Vosters O, Beuneu C, Nagy N, et al. CD40 expression on human pancreatic duct cells: role in nuclear factor-kappa B activation and production of pro-inflammatory cytokines. Diabetologia. 2004 ; 47: 660-668
8. Barbe-Tuana FM, Klein D, Ichii H, et al. CD40-CD40 ligand interaction activates proinflammatory pathways in pancreatic islets. Diabetes. 2006 ; 55: 2437-2445
9. Klein D, Timoneri F, Ichii H, et al. CD40 activation in human pancreatic islets and ductal cells. Diabetologia. 2008 ; 51: 1853-1861
10. Seijkens T, Engel D, Tjwa M, et al. The role of CD154 in haematopoietic development. Thromb Haemost. 2010 ; 104: 693-701
11. Lobbes MB, Lutgens E, Heeneman S, et al. Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. Atherosclerosis. 2006 ; 187: 18-25
12. Hristov M, Gumbel D, Lutgens E, et al. Soluble CD40 ligand impairs the function of peripheral blood angiogenic outgrowth cells and increases neointimal formation after arterial injury. Circulation. 2010 ; 121: 315-324
13. Yacoub D, Hachem A, Theoret JF, et al. Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway. Arterioscler Thromb Vasc Biol. 2010 ; 30: 2424-2433
14. Chai H, Aghaie K, Zhou W. Soluble CD40 ligand induces human coronary artery smooth muscle cells proliferation and migration. Surgery. 2009 ; 146: 5-11
15. Lutgens E, Lievens D, Beckers L, et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med. 2010 ; 207: 391-404
16. Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999 ; 5: 1313-1316
17. Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998 ; 394: 200-203
18. Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: the dark side of a great activator. Semin Immunol. 2009 ; 21: 293-300
19. Gokulakrishnan K, Deepa R, Mohan V, et al. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome - the Chennai Urban Rural Epidemiology Study. Metabolism. 2006 ; 55: 237-242
20. Varo N, Libby P, Nuzzo R, et al. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res. 2005 ; 2: 81-87
21. Marx N, Imhof A, Froehlich J, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation. 2003 ; 107: 1954-1957
22. Poggi M, Engel D, Christ A, et al. CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice. Arterioscler Thromb Vasc Biol. 2011 ; 31: 2251-2260
23. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003 ; 52: 812-817
24. Hummasti S, Hotamisligil GS. Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circ Res. 2010 ; 107: 579-591
25. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011 ; 121: 2111-2117
26. Gonzalez-Chavez A, Elizondo-Argueta S, Gutierrez-Reyes G, et al. Pathophysiological implications between chronic inflammation and the development of diabetes and obesity. Cir Cir. 2011 ; 79: 209-216
27. Poggi M, Jager J, Paulmyer-Lacroix O, et al. The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes. Diabetologia. 2009 ; 52: 1152-1163
28. Missiou A, Wolf D, Platzer I, et al. CD40L induces inflammation and adipogenesis in adipose cells - a potential link between metabolic and cardiovascular disease. Thromb Haemost. 2010 ; 103: 788-796
29. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004 ; 53: S16 - S21
30. Vaidyula VR, Rao AK, Mozzoli M, et al. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes. 2006 ; 55: 202-208
31. Lievens D, Zernecke A, Seijkens T, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood. 2010 ; 116: 4317-4327
32. Oliver SR, Flores RL, Pontello AM, et al. Acute suppression of circulating sCD40L during hyperglycemia and euglycemic-hyperinsulinemia in healthy young males. J Investig Med. 2008 ; 56: 902-910
33. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011 ; 12: 204-212
34. Lutgens E, Cleutjens KB, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA. 2000 ; 97: 7464-7469
35. Wagner AH, Guldenzoph B, Lienenluke B, et al. CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. Arterioscler Thromb Vasc Biol. 2004 ; 24: 715-720
36. Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997 ; 96: 396-399
37. Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA. 1997 ; 94: 1931-1936
38. Bavendiek U, Libby P, Kilbride M, et al. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem. 2002 ; 277: 25032-25039
39. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin - dependent mechanism. Nat Med. 2002 ; 8: 247-252
40. Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol. 2010 ; 7: 369-375
41. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352: 837-853
42. Meier M, Hummel M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc Health Risk Manag. 2009 ; 5: 859-871
43. Hirsch IB, Brownlee M. Beyond hemoglobin A1c - need for additional markers of risk for diabetic microvascular complications. JAMA. 2010 ; 303: 2291-2292
44. Yu PC, Bosnyak Z, Ceriello A. The importance of glycated haemoglobin (HbA(1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes. Diabetes Res Clin Pract. 2010 ; 89: 1-9
45. Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010 ; 123: S3 - S11
46. Tousoulis D, Androulakis E, Papageorgiou N, et al. From atherosclerosis to acute coronary syndromes: the role of soluble CD40 ligand. Trends Cardiovasc Med. 2010 ; 20: 153-164
47. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003 ; 348: 1104-1111
48. Garlichs CD, Eskafi S, Raaz D, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart. 2001 ; 86: 649-655
49. Tousoulis D, Antoniades C, Nikolopoulou A, et al. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest. 2007 ; 37: 623-628
50. Yngen M, Ostenson CG, Hu H, et al. Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia. 2004 ; 47: 537-540
51. Harding SA, Sommerfield AJ, Sarma J, et al. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis. 2004 ; 176: 321-325
52. Lajer M, Tarnow I, Michelson AD, et al. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets. 2010 ; 21: 525-532
53. Katakami N, Kaneto H, Matsuhisa M, et al. Association of soluble CD40 ligand with carotid atherosclerosis in Japanese type 1 diabetic patients. Diabetologia. 2006 ; 49: 1670-1676
54. Nomura S, Shouzu A, Omoto S, et al. Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes. Clin Appl Thromb Hemost. 2004 ; 10: 205-215
55. Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation. 2003 ; 107: 2664-2669
56. Blanco-Colio LM, Martin-Ventura JL, De Teresa E, et al. Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST. Kidney Int Suppl. 2008 ; 111: S60 - S63
57. Chu CS, Lee KT, Lee MY, et al. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol. 2006 ; 97: 646-650
58. Blaha V, Andrys C, Smahelova A, et al. Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover. Pharmacol Res. 2006 ; 54: 421-428
59. Yener S, Comlekci A, Akinci B, et al. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. Med Princ Pract. 2009 ; 18: 266-271
60. Nomura S, Shouzu A, Omoto S, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res. 2008 ; 122: 39-45
61. Mason PJ, Chakrabarti S, Albers AA, et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol. 2005 ; 96: 1365-1369
62. Thom J, Gilmore G, Yi Q, et al. Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J Thromb Haemost. 2004 ; 2: 2067-2069
63. Ahn ER, Lander G, Jy W, et al. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res. 2004 ; 114: 143-148
64. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, et al. Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation. Thromb Res. 2009 ; 123: 617-621
65. Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost. 2010 ; 103: 71-82
66. Goldfine AB, Gerwien RW, Kolberg JA, et al. Biomarkers in fasting serum to estimate glucose tolerance, insulin sensitivity, and insulin secretion. Clin Chem. 2011 ; 57: 326-337
67. Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005 ; 45: 1925-1931
68. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2010 ; 17: 314-321
69. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007 ; 356: 1517-1526